These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39113555)

  • 1. 2024 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong.
    ; Ip TP; Lee CA; Lui TD; Wong RMY; Cheung CL; Chiu KCP; Chow SLE; Ho CF; Ho TC; Ho YA; Lee KK; Li HR; Mak KC; Ng KD; Ngai SLI; Wong CG; Wong SJ; Wong SH; Wong TW
    Hong Kong Med J; 2024 Apr; 30 Suppl 2():1-44. PubMed ID: 39113555
    [No Abstract]   [Full Text] [Related]  

  • 2. The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong.
    ; Ip TP; Cheung SK; Cheung TC; Choi TC; Chow SL; Ho YY; Kan SY; Kung WC; Lee KK; Leung KL; Leung YY; Lo ST; Sy CT; Wong YW;
    Hong Kong Med J; 2013 Apr; 19 Suppl 2():1-40. PubMed ID: 23535738
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effective osteoporosis intervention thresholds for Hong Kong postmenopausal women.
    Kung AW; McGhee SM; Tsang SW; So J; Chau J
    Hong Kong Med J; 2015 Dec; 21 Suppl 6():13-6. PubMed ID: 26645876
    [No Abstract]   [Full Text] [Related]  

  • 4. Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
    Kanis JA; Cooper C; Rizzoli R; Reginster JY;
    Aging Clin Exp Res; 2019 Jan; 31(1):15-17. PubMed ID: 30612282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Osteoporosis therapy. Drugs for strong bones].
    MMW Fortschr Med; 2013 Nov; 155(20):26. PubMed ID: 24482919
    [No Abstract]   [Full Text] [Related]  

  • 6. Denosumab for Reducing Risk of Fractures in Postmenopausal Women.
    Song P; Zehtabchi S
    Am Fam Physician; 2019 May; 99(9):Online. PubMed ID: 31038897
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison table: some drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):e104-e106. PubMed ID: 28609428
    [No Abstract]   [Full Text] [Related]  

  • 8. Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2017 Dec; 59(1536):203-210. PubMed ID: 29232356
    [No Abstract]   [Full Text] [Related]  

  • 9. In postmenopausal women with osteoporosis, romosozumab followed by alendronate reduced fractures vs alendronate alone.
    Hirsch C
    Ann Intern Med; 2018 Jan; 168(2):JC3. PubMed ID: 29335715
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison table: Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2017 Dec; 59(1536):e210-e212. PubMed ID: 29232357
    [No Abstract]   [Full Text] [Related]  

  • 11. Bones, heart and the new anabolic agent romosozumab.
    Pazianas M
    Postgrad Med J; 2019 Oct; 95(1128):521-523. PubMed ID: 31422376
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacologic management of osteoporosis.
    Fontenot HB; Harris AL
    J Obstet Gynecol Neonatal Nurs; 2014; 43(2):236-45; quiz E20-1. PubMed ID: 24502394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abaloparatide (Tymlos) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):97-98. PubMed ID: 28609423
    [No Abstract]   [Full Text] [Related]  

  • 14. Current controversies in clinical management of postmenopausal osteoporosis.
    Kerschan-Schindl K; Mikosch P; Obermayer-Pietsch B; Gasser RW; Dimai HP; Fahrleitner-Pammer A; Dobnig H; Roschger P; Preisinger E; Klaushofer K; Resch H; Pietschmann P
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):437-44. PubMed ID: 24838156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2020 Jul; 62(1602):105-112. PubMed ID: 32728009
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to comments on: Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis.
    Freemantle N; Cooper C; Diez-Perez A; Gitlin M; Radcliffe H; Shepherd S; Roux C
    Osteoporos Int; 2013 Jun; 24(6):1931-2. PubMed ID: 23408019
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment on Freemantle et al.: Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments.
    Brandi ML; Reginster JY; Rizzoli R; Cannata-Andia JB
    Osteoporos Int; 2013 Jun; 24(6):1929-30. PubMed ID: 23408018
    [No Abstract]   [Full Text] [Related]  

  • 18. Celiac disease and bone health: is there a gap in the management of postmenopausal osteoporosis?
    Stuckey BGA; Mahoney LA; Dragovic S; Brown SJ
    Climacteric; 2020 Dec; 23(6):559-565. PubMed ID: 32960111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of osteoporosis therapies in a network meta-analysis with indirect comparisons: many concerns for new tools of evidence synthesis?
    Catalá-López F; Sanfélix-Gimeno G; Tobías A; Hurtado I; Sanfélix-Genovés J; Peiró S
    Osteoporos Int; 2013 Jun; 24(6):1927-8. PubMed ID: 23408017
    [No Abstract]   [Full Text] [Related]  

  • 20. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
    Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
    Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.